RBC keeps Medicines Co. at sector perform

The Medicines Co. was maintained at a sector perform, above average risk, by RBC Capital Markets analyst Jason Kantor as an ongoing barrage of subgroup analyses of Acuity confirms the efficacy of Angiomax and turns up the pressure on its main competitors, the GP 2b/3a inhibitors. A lack of significant new competitive data favors The Medicines Co., according to the analyst. RBC expects the company to announce U.S. sales of $54 million and earnings per share of $0.15. Shares of the Parsippany, N.J.-based pharmaceutical company were down 28 cents, or 1.18%, at $23.45. (Nasdaq: MDCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.